Thrivent Financial For Lutherans grew its holdings in shares of Intersect ENT Inc (NASDAQ:XENT) by 8.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 256,053 shares of the medical equipment provider’s stock after acquiring an additional 20,770 shares during the quarter. Thrivent Financial For Lutherans owned 0.87% of Intersect ENT worth $8,296,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of XENT. Great West Life Assurance Co. Can bought a new stake in shares of Intersect ENT during the 3rd quarter valued at about $116,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Intersect ENT during the 3rd quarter worth approximately $117,000. Bank of Montreal Can purchased a new stake in shares of Intersect ENT during the 4th quarter worth approximately $135,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Intersect ENT during the 3rd quarter worth approximately $228,000. Finally, Simplex Trading LLC purchased a new stake in shares of Intersect ENT during the 4th quarter worth approximately $242,000. Hedge funds and other institutional investors own 84.49% of the company’s stock.
Intersect ENT stock traded down $0.20 during mid-day trading on Thursday, hitting $39.20. The stock had a trading volume of 70,887 shares, compared to its average volume of 259,533. Intersect ENT Inc has a 1-year low of $15.30 and a 1-year high of $40.00.
Intersect ENT (NASDAQ:XENT) last issued its earnings results on Tuesday, February 27th. The medical equipment provider reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.06. Intersect ENT had a negative return on equity of 14.40% and a negative net margin of 16.99%. The business had revenue of $29.53 million for the quarter, compared to analyst estimates of $29.45 million. research analysts expect that Intersect ENT Inc will post -0.59 EPS for the current fiscal year.
In other news, COO Richard E. Kaufman sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $33.33, for a total transaction of $1,666,500.00. Following the completion of the transaction, the chief operating officer now directly owns 107,470 shares in the company, valued at $3,581,975.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Lisa D. Earnhardt sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $38.32, for a total value of $574,800.00. Following the sale, the insider now directly owns 499,683 shares in the company, valued at approximately $19,147,852.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 140,625 shares of company stock valued at $4,894,507. 13.70% of the stock is currently owned by insiders.
Several research firms recently weighed in on XENT. BidaskClub upgraded Intersect ENT from a “hold” rating to a “buy” rating in a report on Thursday. Guggenheim restated a “buy” rating on shares of Intersect ENT in a research note on Thursday, March 1st. Zacks Investment Research upgraded Intersect ENT from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $36.00 price objective on shares of Intersect ENT in a report on Monday, December 11th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $33.38.
TRADEMARK VIOLATION NOTICE: This story was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2018/03/22/thrivent-financial-for-lutherans-grows-position-in-intersect-ent-inc-xent.html.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.